Sexual HealthAgendia Opens CLIA-Registered U.S. Genomics Laboratory
Agendia, a world leader in molecular cancer diagnostics,
announced the opening of its U.S. clinical genomics laboratory in Huntington
Beach, CA. The laboratory is fully-licensed and compliant with the Clinical
Laboratory Improvements Amendments (CLIA) as administered by the Centers for
Medicare and Medicaid Services (CMS).
In addition to opening its U.S. cancer genomics laboratory,
Agendia has over the past months made several key additions to its
domestic-based senior executive team. The team consists of Dr. Richard
Bender, Chief Medical Officer, Mr. Daniel Forche, Vice President of Sales &
Marketing, Mr. Alan B. Carter, Vice President of Global Business Development,
and pathologist Dr. Chynel Henning, Laboratory Director.
"Our new genomics lab"s capacity will allow us to meet the
increasing demand for MammaPrint across the United States and give physicians
and patients optimal test result turnaround and unmatched service and
support," noted Jan Groen, Ph.D., Chief Operating Officer. "This expansion
places us in an excellent position to continue making advancements in
molecular cancer diagnostics and equip oncologists with powerful tools to use
in the fight against breast cancer."
Dr. Bernhard Sixt, President and Chief Executive Officer,
added, "the opening of the Huntington Beach laboratory and the appointment of
our U.S.-based commercial team provide a strong basis for our U.S. operations
and for Agendia"s next phase of growth. Our enhanced domestic capabilities
will help us to further drive adoption of MammaPrint, and place us in an even
better position to collaborate with a growing number of clinical, academic,
and industrial partners here in the U.S."
Dr. Bender has more than 30 years of medical and professional
experience as a practicing oncologist and director of several oncology
programs. Dr. Bender has served as Medical Director of the
Hematology/Oncology Program at Quest Diagnostics, Director of Medical
Oncology and Hematology at Kaiser Permanente Medical Group, Director of
Strategic Development in Medical Oncology/Hematology at Johnson & Johnson,
and as an investigator at the National Cancer Institute and Scripps Clinic
and Research Foundation. Currently, Dr. Bender serves as an expert reviewer
in oncology for the Medical Board of California, co-Editor of Anti-Cancer
Drugs, an international journal on anti-cancer agents, and as a clinical
instructor in medicine at the University of California, Irvine School of
Medicine.
Mr. Forche brings more than 18 years of sales, marketing and
commercial leadership experience in the diagnostics arena. Prior to joining
Agendia, Mr. Forche was the Senior Vice President of Sales and Marketing for
Insight Health Corporation, a national leader in diagnostic imaging services.
He also served as Vice President of Marketing at US LABS, an industry leader
in cancer diagnostic and genomic testing services, and has held sales and
marketing management roles at Ventana Medical Systems (now Roche) and Abbott
Laboratories.
Mr. Carter joins Agendia with 25 years of global business
development experience from a number of top-tier life sciences companies such
as BioTrove, Celera, Applied Biosystems, and Perkin Elmer. At Agendia, he
oversees ongoing strategic alliances within the bio-pharmaceutical sector and
collaboration with partners interested in Agendia"s expanding molecular
diagnostics portfolio.
Chynel Henning, M.D., Ph.D., FASCP, FCAP, joins Agendia with
more than 30 years of experience as a laboratory director. He is currently
also Director of National Cyto-Path Laboratories and Professional Pathology
Medical Group Laboratory, both in Long Beach, California; and Director of the
Laboratory and Department of Pathology at the Miracle Mile Medical Center,
Los Angeles. Dr. Henning is a Fellow of the American Society of Clinical
Pathologists and the College of American Pathologists.
Ongoing research and development commitments continue to
augment Agendia"s ability to accurately predict breast cancer recurrence and
sub-typing, and help physicians tailor individual treatment plans to their
patients. Agendia"s goal is to provide women with answers to crucial
treatment questions, such as how their breast cancer will respond to targeted
therapies or various chemotherapy regimens.
Agendia B.V.